Rallybio Corporation  (RLYB)
Other Ticker:  
Price: $1.8000 $0.10 5.882%
Day's High: $1.88 Week Perf: -1.64 %
Day's Low: $ 1.73 30 Day Perf: 28.57 %
Volume (M): 307 52 Wk High: $ 9.88
Volume (M$): $ 553 52 Wk Avg: $4.48
Open: $1.76 52 Wk Low: $1.23

 Market Capitalization (Millions $) 73
 Shares Outstanding (Millions) 41
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -33
 Capital Exp. (TTM) (Millions $) 0

Rallybio Corporation
Rallybio Corporation is a US-based biopharmaceutical company that is focused on the development of novel treatments for rare and serious diseases. Founded in 2018, the company has quickly become one of the leading players in the biotech industry, thanks to its innovative drug discovery platform and strong team of scientists, researchers, and business professionals.

The mission of Rallybio Corporation is to discover and develop life-changing therapies that can address unmet medical needs in patients with rare diseases. The company is dedicated to advancing the science of drug development and pushing the boundaries of what is possible in the field of biotechnology.

One of the key strengths of Rallybio Corporation is its deep expertise in the biology of rare diseases. The company's team of experts includes some of the most renowned scientists and researchers in the field, who have a wealth of experience in the discovery and development of new treatments for rare and orphan diseases.

Rallybio Corporation is currently focusing on the development of a pipeline of innovative drug candidates that have the potential to transform the lives of patients with rare and serious illnesses. The company's lead program is a monoclonal antibody therapy designed to treat patients with severe hemophilia A.

In addition to its lead program, Rallybio Corporation has a number of other drug candidates in the pipeline, including treatments for rare genetic disorders such as lysosomal storage diseases, immune-mediated diseases, and other serious conditions.

One of the key factors that sets Rallybio Corporation apart from its competitors is its strategic approach to drug development. The company is focused on developing targeted therapies that address the specific molecular mechanisms that underlie rare diseases, which enables them to deliver highly effective and precise treatments that have minimal side effects.

Overall, Rallybio Corporation is an exciting and dynamic biotech company that is making significant strides in the discovery and development of innovative drug therapies for rare and serious diseases. With its strong team of experts and cutting-edge technology platform, the company is well-positioned to become a major player in the biotech industry over the coming years.

   Company Address: 234 Church Street New Haven 6510 CT
   Company Phone Number: 859-3820   Stock Exchange / Ticker: NASDAQ RLYB
   RLYB is expected to report next financial results on March 05, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Rallybio Corporation

Rallybio Corporation Reports Operating Shortfall for Q3 2023 Amidst Challenges Faced by Emerging Pharmaceutical Company

Rallybio Corporation, an emerging pharmaceutical preparations company, recently reported an operating shortfall of $-19.363 million for the third quarter of 2023. This article aims to provide a balanced and informative overview of the company's financial performance, including a comparison with the same period in 2022. Additionally, the article highlights the recent decline in Rallybio Corporation's stock value and its 52-week low.
Operating Shortfall in Q3 2023
Rallybio Corporation's operating shortfall of $-19.363 million for the third quarter of 2023 indicates a slight increase from the operating shortfall of $-18.86 million in the same period the previous year. While this may come as a disappointment for the company, it is important to note that emerging growth firms often face financial challenges in their early years.
Comparing the net deficit for Q3 2023 with Q3 2022, Rallybio Corporation saw a minimal increase from $-18.370 million to $-18.374 million. Although the figures are not significantly different, they highlight a consistent struggle to achieve profitability during this period.

Rallybio Corporation

Major Pharmaceutical Preparations Company, Rallybio Corporation, Reports Operating Deficit of $-20.083 Million in Q2 2023, Signaling Challenging Times Ahead in Revenue Streams

Rallybio Corporation, a major player in the pharmaceutical preparations sector, is currently gaining attention from researchers as they analyze the company's second-quarter earnings for 2023. Despite not disclosing their top-line figures yet, the corporation reported an operating deficit of $-20.083 million for the period between April and June 30, 2023.
To fully understand the significance of these results, it is important to examine the company's performance in the previous year. In the second quarter of 2022, Rallybio Corporation recorded an operating deficit of $-17.615 million. This comparison allows us to see that the operating deficit has increased to $-18.630 million in the second quarter of 2023, potentially highlighting some challenging periods for the corporation's revenue streams.

Rallybio Corporation

Breaking News: Major Pharmaceutical Powerhouse Faces Setback with Operating Loss in Q1 of 2023

Rallybio Corporation, a rising company in the Major Pharmaceutical Preparations industry, has announced an operating loss of $-18.374 million for the first quarter of 2023. Although the company has not disclosed its revenue for the quarter, previous performances indicate that the loss is within expectations for a developing company in the industry.
During the same period in 2022, Rallybio Corporation revealed an operating loss of $-14.318 million. However, the management is committed to implementing various corporate policies to ensure the provision of a consistent service. Despite the deficit, the company has been able to extend its range of services and activities, a positive sign for investors and stakeholders.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com